Compare FPI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | ALLO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.8M | 539.4M |
| IPO Year | 2013 | 2018 |
| Metric | FPI | ALLO |
|---|---|---|
| Price | $11.79 | $2.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $8.73 |
| AVG Volume (30 Days) | 386.6K | ★ 7.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $144,130.60 |
| P/E Ratio | $19.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.37 | $0.86 |
| 52 Week High | $13.23 | $4.46 |
| Indicator | FPI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 48.36 |
| Support Level | $10.84 | $2.14 |
| Resistance Level | $12.35 | $2.71 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 91.79 | 8.85 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.